Sensibilité in vitro des souches de Candida albicans d’origine vaginale aux antifongiques à Abidjan (Côte d’Ivoire)

Denis, Vincent; Angora, Kpongbo Etienne; Vanga-Bosson, A.H.; Konaté, A.; Kassi, F.K.; Yavo, William; Kiki-Barro, Pulchérie Christiane; Menan, H.; Koné, Mamidou Witabouna

doi:10.1016/j.mycmed.2011.11.005

Cited by 18 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…C. albicans resistance to amphotericin B has also been reported in Kenya (25.6%) 32 and Ghana (23.4%) 39 , while no resistance was seen in studies from Ivory Coast 30, 38 nor Nigeria 29 . Intermediate resistance values observed for clotrimazole and amphotericin B in studies from South West Cameroon, may indicate the need for administering higher doses to effectively treat these patients.…”

Section: Resultsmentioning

confidence: 93%

“…This review included seven studies from two regions in South Africa 22– 25, 36, 40, 41 , three studies from different regions in Ethiopia 33– 35 , three studies from two regions in Cameroon 25– 27 , three studies from different regions in Nigeria 28, 29, 37 , two studies from the same region in Ivory Coast 30, 38 , one study from Tanzania 31 , one study from Kenya 32 and one study from Ghana 39 . Due to the paucity of studies and differences in isolation and antifungal susceptibility testing, a meta-analysis could not be conducted.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Candida antifungal drug resistance in sub-Saharan African populations: A systematic review

Africa

Abrantes

2017

F1000Res

View full text Add to dashboard Cite

Background: Candida infections are responsible for increased morbidity and mortality rates in at-risk patients, especially in developing countries where there is limited access to antifungal drugs and a high burden of HIV co-infection. Objectives: This study aimed to identify antifungal drug resistance patterns within the subcontinent of Africa. Methods: A literature search was conducted on published studies that employed antifungal susceptibility testing on clinical Candida isolates from sub-Saharan African countries using Pubmed and Google Scholar. Results: A total of 21 studies from 8 countries constituted this review. Only studies conducted in sub-Saharan Africa and employing antifungal drug susceptibility testing were included. Regional differences in Candida species prevalence and resistance patterns were identified. Discussion: The outcomes of this review highlight the need for a revision of antifungal therapy guidelines in regions most affected by Candida drug resistance. Better controls in antimicrobial drug distribution and the implementation of regional antimicrobial susceptibility surveillance programmes are required in order to reduce the high Candida drug resistance levels seen to be emerging in sub-Saharan Africa.

show abstract

Section: Resultsmentioning

confidence: 93%

Section: Resultsmentioning

confidence: 99%

Candida antifungal drug resistance in sub-Saharan African populations: A systematic review

Africa

Abrantes

2017

F1000Res

View full text Add to dashboard Cite

show abstract

“…In fact, recurrent vulvovaginal candidiasis is caused mostly by Candida spp., especially by C. glabrata (Sobel, 2015;Denning et al, 2018). The occurrence of these fungal agents in vulvovaginal candidiasis etiology was previously mentioned in Côte d"Ivoire with prevalence rates ranging from 10 to 32,7% (Bonouman-Ira et al, 2011;Djohan et al, 2012;Konaté et al, 2014) where C. glabrata was also considered predominant. The other species observed were C. tropicalis, C. krusei, Candida parapsilosis and seldom Candida famata (Richter et al, 2005) susceptibility rates vary according to the Candida spp.…”

Section: Discussionmentioning

confidence: 89%

“…Studies about candidiasis in Côte d"Ivoire showed the antifungal susceptibility pattern of the Candida spp. from vulvovaginal candidiasis (Djohan et al, 2012;Konaté et al, 2014). But there is no data available about recurrent vulvovaginal candidiasis, hence the importance of this study which aims to determine the antifungal susceptibility of Candida spp.…”

Section: Introductionmentioning

confidence: 99%

Susceptibility of Candida species isolated from recurrent vulvovaginal candidiasis to antifungal agents among women at Institut Pasteur of Cte dIvoire

Angora¹,

Denis²,

Ira-Bonouman³

et al. 2018

J. Yeast Fungal Res.

View full text Add to dashboard Cite

Recurrent vulvo-vaginal candidiasis is a major issue in pubescent females because of the fact that it is a source of health discomfort. For a better medical treatment, an analysis of susceptibility of Candida species to antifungal agents is fundamental. Therefore, this study aims to determine the susceptibility of Candida spp. to antifungal agents isolated in recurrent vulvo-vaginal candidiasis. This crosssectional study was carried out in 2014 among 400 women with vaginal discharge. The recurrent vulvovaginitis was defined by the occurrence four times at least in a year. Vaginal swabs were cultured on Sabouraud-chloramphenicol medium, and Candida spp. were identified using a chromogenic technique. Susceptibility testing was performed using a microdilution method. In vitro susceptibility to antifungal agents test was performed using amphotericin B, 5-fluorocytosine, fluconazole, itraconazole and voriconazole against isolated Candida spp. Of 94 women positive from Candida spp., Candida albicans (59.6%) was the most prevalent with 59.6%. C. albicans did not show any resistance to amphotericin B and voriconazole. The susceptibility Candida glabrata to itraconazole was 50% and this species was relatively susceptible to fluconazole (77.8%) and voriconazole (83.3%). The medical treatment of recurrent vulvovaginal candidiasis requires a precise diagnosis based on a mycological analysis and the susceptibility to antifungal drugs.

show abstract

“…(Morgan et al, 2005;Lass-Flörl, 2009;Pfaller and Diekema, 2007). Therapeutic support management of these infections constitutes a public health issue with emergence of drug resistant strains to most of the current antifungals [Djohan et al, 2012;Bryskier, 1999;Sanglard and Odds, 2002). This drug resistance is more alarming with azoles antifungals which are the most commonly used drug class (Espinel-Ingroff, 2008;Smagill et al, 2007).…”

Section: Introductionmentioning

confidence: 99%

Synthesis and antifungal activities of some benzimidazolyl-chalcones, analogues of chlormidazole

Sissouma¹,

Ouattara²,

Mamidou³

2015

Afr. J. Pharm. Pharmacol.

View full text Add to dashboard Cite

show abstract

Sensibilité in vitro des souches de Candida albicans d’origine vaginale aux antifongiques à Abidjan (Côte d’Ivoire)

Cited by 18 publications

References 35 publications

Candida antifungal drug resistance in sub-Saharan African populations: A systematic review

Candida antifungal drug resistance in sub-Saharan African populations: A systematic review

Susceptibility of Candida species isolated from recurrent vulvovaginal candidiasis to antifungal agents among women at Institut Pasteur of Cte dIvoire

Synthesis and antifungal activities of some benzimidazolyl-chalcones, analogues of chlormidazole

Contact Info

Product

Resources

About